Orexigen Therapeutics (OREX) Remains Outperform Rated at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Orexigen Therapeutics (OREX) Tops Q3 EPS by 22c
November 10, 2014 7:47 AM ESTOrexigen Therapeutics (NASDAQ: OREX) reported Q3 EPS of $0.09, $0.22 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $30.9 million versus the consensus estimate of $8.93 million.
For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.
... More